Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877915 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,081
- Enrollment target
NCT01877915 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 5,081 participants.
The verdict
NCT01877915, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,081 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.
Interventions
- DRUG Placebo
- DRUG Rivaroxaban
- OTHER Standard of care for heart failure and coronary artery disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,081 participants |
| Start Date | 2013-09-10 |
| Est. Completion | 2018-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877915
The ClinicalTrials.gov registry entry for NCT01877915 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,081 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01877915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877915 about?
NCT01877915 is a clinical study titled "A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure". The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensa...
What is the current status of trial NCT01877915?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,081 participants. The study started on 2013-09-10. Estimated completion is 2018-04-19.
What interventions are being tested in trial NCT01877915?
The interventions under investigation include: Placebo (DRUG), Rivaroxaban (DRUG), Standard of care for heart failure and coronary artery disease (OTHER).
Who is sponsoring clinical trial NCT01877915?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.